| Literature DB >> 32334484 |
Bijina T K1,2, Ganesh K M3, Pichandi A2, Muthuselvi C A2.
Abstract
BACKGROUND: This study was conducted to dosimetrically compare plan quality of Simultaneous Integrated Boost - Stereotactic Body Radiotherapy (SIB-SBRT) generated for different techniques such as Cyberknife (CK), Helical Tomotherapy (HT) and RapidArc (RA) for carcinoma prostate with same treatment margins.Entities:
Keywords: CyberKnife; Helical tomotherapy; Prostate Cancer; RapidArc; SIB-SBRT
Year: 2020 PMID: 32334484 PMCID: PMC7445956 DOI: 10.31557/APJCP.2020.21.4.1149
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Dose Constraints
| Structure | Volume | Constraints |
|---|---|---|
| GTV45 | % volume receiving 45 Gy | 95% |
| GTV37.5 | % volume receiving 37.5 Gy | 95% |
| Rectum | % receiving 37.5 Gy | <5% |
| % receiving 30 Gy | <20% | |
| % receiving 18.75Gy | <50% | |
| Maximum dose to 1 cm3 | 39.5Gy | |
| Bladder | % receiving 37.5 Gy | <5% |
| % receiving 18.75 Gy | <50% | |
| Maximum dose to 1 cm3 | 39.5Gy | |
| Femoral heads | Maximum point dose | 30 Gy |
Comparison of Dose to Gross Tumor Volume (GTV45) and Planning Target Volume (PTV37.5) Among Different Treatment Techniques
| DVH parameters | CK | HT | RA | ( | ||
|---|---|---|---|---|---|---|
| CK vs HT | HT vs RA | RA vs CK | ||||
| GTV45 | ||||||
| D2% (Gy) | 49.03 ± 0.91 | 47.45 ± 0.72 | 47.88 ± 0.39 | <0.001* | 0.273 | 0.001* |
| D98% (Gy) | 44.45 ± 0.42 | 45.30 ± 0.22 | 44.57 ± 0.21 | <0.001* | <0.001* | 0.592 |
| D50% (Gy) | 47.18 ± 0.74 | 46.41 ± 0.46 | 46.46 ± 0.31 | 0.002* | 0.964 | 0.004* |
| Mean Dose (Gy) | 47.03 ± 0.63 | 46.39 ± 0.39 | 46.42 ±0.25 | 0.003* | 0.993 | 0.004* |
| PTV37.5 | ||||||
| D2% (Gy) | 46.37 ± 0.92 | 45.19 ± 0.79 | 43.97 ± 0.38 | 0.001* | <0.001* | <0.001* |
| D98% (Gy) | 36.27 ± 0.96 | 36.97 ± 0.75 | 36.54 ± 0.37 | 0.051 | 0.290 | 0.637 |
| D50% (Gy) | 41.04 ± 0.61 | 40.89 ± 0.66 | 40.61 ± 0.58 | 0.819 | 0.475 | 0.191 |
| Mean Dose (Gy) | 40.96 ± 0.49 | 40.87 ± 0.57 | 40.57 ± 0.43 | 0.868 | 0.311 | 0.129 |
*, indicates the differences to be statistically significant (P<0.05); Values represent Mean±SD; CK, Cyberknife; HT, Helical Tomotherapy; RA, Rapidarc; D2%, Dose to 2% volume; D98%, Dose to 98% volume; D50%, Dose to 50% volume
Figure 1Comparison of Dose Distribution Among Three Techniques Axial Slice Showing Isodose Distribution Planned for (A) Cyberknife (B) Helical Tomotherpy and (C) Rapidarc
Figure 2Comparison of Gradient Index, GI75 – Ratio of 75% Isodose Volume to Prescription Isodose Volume, GI50 – Ratio of 50% Isodose Volume to Prescription Isodose Volume, GI25 – Ratio of 25% Isodose Volume to Prescription Isodose Volume
Comparison of Dosimetric Indices Among the Three Treatment Techniques
| Dosimetric indices | CK | HT | RA | ( | ||
|---|---|---|---|---|---|---|
| CK vs HT | HT vs RA | RA vs CK | ||||
| Gradient indices | ||||||
| GI75 | 2.61 ± 0.54 | 2.67 ± 0.40 | 1.83 ± 0.22 | 0.918 | <0.001* | <0.001* |
| GI50 | 4.97 ± 0.86 | 5.45 ± 0.82 | 3.78 ± 0.25 | 0.213 | <0.001* | <0.001* |
| GI25 | 18.48 ± 4.51 | 21.81 ± 3.45 | 17.99 ± 1.63 | 0.043* | 0.019* | 0.935 |
| Conformity indices | ||||||
| PTV37.5 | 0.75 ± 0.07 | 0.74 ± 0.07 | 0.89 ± 0.01 | 0.863 | <0.001* | <0.001* |
| GTV45 | 0.35 ± 0.11 | 0.49 ± 0.15 | 0.71 ± 0.11 | 0.017* | <0.001* | <0.001* |
*, indicates the differences to be statistically significant (P<0.05); Values represent Mean±SD; CK, Cyberknife; HT, Helical Tomotherapy; RA, Rapidarc; GI75, Ratio of 75% of prescription dose to presctiption volume,;GI50, Ratio of 50% of prescription dose to presctiption volume.
Figure 3VPTV37.5 vs V5Gy; VPTV37.5 – Volume of PTV37.5, V5Gy – Volume of Body Receiving 5Gy
Comparison of other Variables Like Integral Dose, V5Gy (cc), Monitor Units (MUs) and Beam Time Among the Three Different Types of Treatment
| Variables | CK | HT | RA | ( | ||
|---|---|---|---|---|---|---|
| CK vs HT | HT vs RA | RA vs CK | ||||
| ID (Gy-L) | 86.50±18.58 | 57.15±14.28 | 50.94±16.06 | <0.001* | 0.603 | <0.001* |
| V5Gy (cc) | 3934.62±1229.52 | 3715.41±1113.49 | 3312.33±855.14 | 0.863 | 0.610 | 0.316 |
| MUs/fr | 13419.68±1739.68 | 9565.23±1315.38 | 3277.77±497.94 | <0.001* | <0.001* | <0.001* |
| BOT (min) | 22.37±2.89 | 11.12±1.33 | 2.54±0.38 | <0.001* | <0.001* | . <0.001* |
*, indicates the differences to be statistically significant (P<0.05); Values represent Mean±SD; CK, Cyberknife; HT, Helical Tomotherapy; RA, Rapidarc; ID, Integral dose; V5Gy, Volume receiving 5Gy; MUs/fr, Monitor units per fraction; BOT, Beam on time
Comparison of Dose Delivery to the Organs at Risk (OARs) Among the Three Different Types of Treatment
| Dose to OARs | CK | HT | RA | (P-value) | ||
|---|---|---|---|---|---|---|
| CK vs HT | HT vs RA | RA vs CK | ||||
| Bladder | ||||||
| V 80% (%) | 1.45 ± 0.89 | 1.39 ± 1.10 | 0.33 ± 0.38 | 0.982 | 0.008* | 0.005* |
| V 50% (%) | 14.82 ± 6.74 | 13.71 ± 5.89 | 6.88 ± 2.73 | 0.859 | 0.008* | 0.002* |
| V 20% (%) | 51.87 ± 14.55 | 47.51 ± 12.15 | 38.24 ± 7.42 | 0.616 | 0.124 | 0.015* |
| DMean (Gy) | 12.63 ± 1.91 | 11.12 ± 2.83 | 8.63 ± 1.41 | 0.181 | 0.014 | <0.001* |
| D2% (Gy) | 34.82 ± 2.17 | 34.14 ± 2.96 | 28.75 ± 2.88 | 0.799 | <0.001* | <0.001* |
| Rectum | ||||||
| V 80% (%) | 1.56 ± 1.07 | 1.96 ± 1.32 | 0.27 ± 0.23 | 0.563 | <0.001* | 0.005* |
| V 50% (%) | 16.60 ± 4.52 | 17.66 ± 4.75 | 6.96 ± 2.26 | 0.779 | <0.001* | <0.001* |
| V 20% (%) | 59.49 ± 8.40 | 58.59 ± 9.89 | 45.76 ± 9.71 | 0.967 | 0.004* | 0.002* |
| DMean (Gy) | 13.28 ± 1.66 | 12.52 ± 2.61 | 9.59 ± 1.35 | 0.586 | 0.001* | <0.001* |
| D2% (Gy) | 34.67 ± 1.49 | 35.51 ± 1.86 | 29.13 ± 2.53 | 0.543 | <0.001* | <0.001* |
| Right Femur | ||||||
| DMean (Gy) | 7.15 ± 1.42 | 8.92 ± 1.57 | 8.72 ± 2.06 | 0.114 | 0.834 | 0.033* |
| D2% (Gy) | 11.16 ± 1.39 | 12.62 ± 1.97 | 13.03 ± 2.01 | 0.031 | 0.949 | 0.063 |
| Left Femur | ||||||
| DMean (Gy) | 5.42 ± 0.99 | 8.29 ± 1.55 | 8.79 ± 2.04 | 0.016 | 0.982 | 0.010* |
| D2% (Gy) | 10.64 ± 1.44 | 12.34 ± 1.69 | 12.44 ± 1.29 | <0.001* | 0.707 | <0.001* |
*, indicates the differences to be statistically significant (P<0.05); V80%, Volume receiving 80% of prescription dose; V50%, Volume receiving 50% of prescription dose; V20%, Volume receiving 20% of prescription dose, DMean, Mean dose, D2%, Dose to 2% volume